Newsroom – XENOTHERA

Home
-
Newsroom

~~Latest news~~

XENOTHERA confirms progress in the treatment of peripheral T-cell lymphoma (PTCL) through its LIS22 antibody

June, 2025, Nantes-based biotech XENOTHERA confirms the value of its LIS22 antibody in the treatment of peripheral T-cell lymphomas (PTCL). The PALT1 clinical trial (NCT06495723) has just passed a new milestone

XENOTHERA Welcomes the National Academy of Medicine’s Call for a National Xenotransplantation Plan and Reaffirms Its Commitment to This Breakthrough Medical Innovation

May, 2025. XENOTHERA, a French biotechnology company based in Nantes and a pioneer in the development of genetically modified pigs for therapeutic purposes, welcomes the publication of the National Academy of Medicine's report…

XENOTHERA reaches important milestones in its oncology and onco-hematology clinical trials.

December, 2024. XENOTHERA reaches important milestones in its oncology and onco-hematology clinical trials….

XENOTHERA successfully secures €4 Million non-dilutive financing from the France 2030 Public Investment Plan for its LIS22 treatment for peripheral T-Cell lymphoma.

November, 2024. The PALT24 project (Polyspecific Antibodies in Lymphoproliferative T cell disorders) targets a critical onco-hematological disease with a notably low prognosis.

XENOTHERA presents XON11, a new hope for the treatment of pancreatic cancer

October, 2024. At the 36th ENA - EORTC - AACR symposium, Firas Bassissi, XENOTHERA CSO, presented highly promising results in pancreatic cancer.

XENOTHERA ANNOUNCES THE RECRUITMENT OF THE FIRST PATIENT OF THE PALT1 TRIAL IN PERIPHERAL T-CELL LYMPHOMA (PTCL) AND ITS ORPHAN DRUG STATUS (ODD) BY THE EMA

August 24. Treatment with its antibody directed against tumor lymphocytes offers new hope for patients with PTCL

XENOTHERA publishes the clinical efficacy of XAV-19, its anti-COVID antibody, in Frontiers in Immunology

June, 2024. During its participation in ASCO, XENOTHERA….

XENOTHERA reports to ASCO on the clinical trial of its first anti-cancer drug, XON7, and announces a financing agreement with BPI France

June, 2024. During its participation in ASCO, XENOTHERA….

[Press Release] New hope for patients: XENOTHERA granted orphan drug designation (ODD ) from the FDA for LIS1 in the treatment of T-lymphomas.

September 12, 2023. # Download our press release (english version) # Télécharger...

[Press Release] XENOTHERA strengthens its management team and governance.

June 8, 2023. # Download our press release (english version) # Télécharger...

[Press Release] XENOTHERA publishes its results at the World Cancer Congress in Chicago (ASCO) June 2-6, 2023.

May 30, 2023. # Download our press release (english version) # Télécharger...

[Communiqué officiel] À l’occasion du déplacement du Président de la République française, Emmanuel Macron, XENOTHERA est présente en Chine pour suivre un programme Business organisé par Business France.

April 5,2023. # Télécharger notre communiqué de presse (version française)

[Press Release] The French biotech XENOTHERA, on a mission with business France in China

April 3, 2023. # Download our press release (english version) # Télécharger...

[Press Release] XAV-19, the anti-SARS-CoV-2 GH-pAb of XENOTHERA best-in-class against all variants including BQ. 1.1

January 05,2023. # Download our press release (english version)

[Press Information] Orphan designation by the European Medicines Agency for LIS1, the transplant induction therapy from XENOTHERA

July 11th, 2022. # Download our press information (english version) # Télécharger...

[Press Information] Orphan designation by the European Medicines Agency for LIS1, the transplant induction therapy from XENOTHERA

July 11th, 2022. # Download our press information (english version) # Télécharger...

XENOTHERA confirms progress in the treatment of peripheral T-cell lymphoma (PTCL) through its LIS22 antibody

XENOTHERA Welcomes the National Academy of Medicine’s Call for a National Xenotransplantation Plan and Reaffirms Its Commitment to This Breakthrough Medical Innovation

XENOTHERA reaches important milestones in its oncology and onco-hematology clinical trials.

XENOTHERA successfully secures €4 Million non-dilutive financing from the France 2030 Public Investment Plan for its LIS22 treatment for peripheral T-Cell lymphoma.

XENOTHERA presents XON11, a new hope for the treatment of pancreatic cancer

XENOTHERA ANNOUNCES THE RECRUITMENT OF THE FIRST PATIENT OF THE PALT1 TRIAL IN PERIPHERAL T-CELL LYMPHOMA (PTCL) AND ITS ORPHAN DRUG STATUS (ODD) BY THE EMA

XENOTHERA publishes the clinical efficacy of XAV-19, its anti-COVID antibody, in Frontiers in Immunology

XENOTHERA reports to ASCO on the clinical trial of its first anti-cancer drug, XON7, and announces a financing agreement with BPI France

Reflections on #AACR2024: our key insights and contributions

XENOTHERA announces the start of the second dose cohort in the FIPO trial

XENOTHERA : publication of the first-in-human trial of LIS1 in Solid Organ Transplantation

[Press Release] XENOTHERA recruits the first patient in the clinical trial of XON7, its new anti-cancer treatment

[Press Release] French biotech announces its therapeutic potential for oxygen-free patients

[Press Release] New hope for patients: XENOTHERA granted orphan drug designation (ODD ) from the FDA for LIS1 in the treatment of T-lymphomas.

[Press Release] XENOTHERA strengthens its management team and governance.

[Press Release] XENOTHERA publishes its results at the World Cancer Congress in Chicago (ASCO) June 2-6, 2023.

[Communiqué officiel] À l’occasion du déplacement du Président de la République française, Emmanuel Macron, XENOTHERA est présente en Chine pour suivre un programme Business organisé par Business France.

[Press Release] The French biotech XENOTHERA, on a mission with business France in China

[Press Release] XAV-19, the anti-SARS-CoV-2 GH-pAb of XENOTHERA best-in-class against all variants including BQ. 1.1

[Press Information] Orphan designation by the European Medicines Agency for LIS1, the transplant induction therapy from XENOTHERA

[Press Alert] XENOTHERA announces the efficacy of its XAV-19 antibody against the BQ.1.1variant.

[Press Release] XAV-19: end of EUROXAV clinical trial and positive trends for the XENOTHERA antibody.

[Newsletter] XENONEWS

[Press Information] Orphan designation by the European Medicines Agency for LIS1, the transplant induction therapy from XENOTHERA